Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, Hunan, China.
University of South China, Hengyang, 421001, Hunan, China.
Exp Mol Med. 2023 Jul;55(7):1357-1370. doi: 10.1038/s12276-023-01020-1. Epub 2023 Jul 3.
Metabolic reprogramming and epigenetic modifications are hallmarks of cancer cells. In cancer cells, metabolic pathway activity varies during tumorigenesis and cancer progression, indicating regulated metabolic plasticity. Metabolic changes are often closely related to epigenetic changes, such as alterations in the expression or activity of epigenetically modified enzymes, which may exert a direct or an indirect influence on cellular metabolism. Therefore, exploring the mechanisms underlying epigenetic modifications regulating the reprogramming of tumor cell metabolism is important for further understanding tumor pathogenesis. Here, we mainly focus on the latest studies on epigenetic modifications related to cancer cell metabolism regulations, including changes in glucose, lipid and amino acid metabolism in the cancer context, and then emphasize the mechanisms related to tumor cell epigenetic modifications. Specifically, we discuss the role played by DNA methylation, chromatin remodeling, noncoding RNAs and histone lactylation in tumor growth and progression. Finally, we summarize the prospects of potential cancer therapeutic strategies based on metabolic reprogramming and epigenetic changes in tumor cells.
代谢重编程和表观遗传修饰是癌细胞的标志。在癌细胞中,代谢途径的活性在肿瘤发生和癌症进展过程中发生变化,表明代谢具有调节的可塑性。代谢变化通常与表观遗传变化密切相关,例如表观遗传修饰酶的表达或活性的改变,这些改变可能对细胞代谢产生直接或间接的影响。因此,探索表观遗传修饰调节肿瘤细胞代谢重编程的机制对于进一步了解肿瘤发病机制非常重要。在这里,我们主要关注与癌症细胞代谢调控相关的表观遗传修饰的最新研究,包括在癌症背景下葡萄糖、脂质和氨基酸代谢的变化,然后强调与肿瘤细胞表观遗传修饰相关的机制。具体来说,我们讨论了 DNA 甲基化、染色质重塑、非编码 RNA 和组蛋白乳酸化在肿瘤生长和进展中的作用。最后,我们总结了基于肿瘤细胞代谢重编程和表观遗传变化的潜在癌症治疗策略的前景。
Protein Cell. 2022-12
Clin Cancer Res. 2017-8-1
Semin Cancer Biol. 2022-8
Ernst Schering Res Found Workshop. 2006
Front Biosci (Landmark Ed). 2020-3-1
Mol Ther Nucleic Acids. 2025-7-30
Front Pharmacol. 2025-7-18
World J Clin Oncol. 2025-7-24
Altern Ther Health Med. 2022-2
Cancer Res. 2022-3-15
Cancer Discov. 2022-1
Trends Immunol. 2022-1
Eur J Radiol. 2022-2